The bivalirudin strategy was statistically noninferior to the UFH plus GPI strategy with respect to the primary end point of 30-day death, MI, target vessel revascularization or major bleeding.

Regardless, any amount of bleeding is now known to portend significant increases in the risk of ischemic complications such as MI and stroke, as well as death. Understanding this association ...